Immatics (IMTX)

Executive Summary

Immatics is a clinical-stage biopharmaceutical company pioneering TCR-based immunotherapies for solid cancers. The company leverages proprietary discovery platforms to identify cancer-specific targets, with a leading focus on PRAME-targeting therapeutics across multiple modalities. Its most advanced program, IMA203, an autologous TCR-T cell therapy targeting PRAME, is currently being evaluated in a Phase 1/2 trial for refractory solid tumors and a Phase 3 trial for cutaneous malignant melanoma. Immatics has a robust pipeline including combination studies with checkpoint inhibitors and mRNA vaccines. With a strong scientific foundation and strategic partnerships, the company is well-positioned to address high unmet needs in oncology.

Upcoming Catalysts (preview)

• H2 2026IMA203 Phase 3 Melanoma Trial Interim Data60% success
• H1 2026IMA203 Phase 1/2 Solid Tumor Update65% success
• TBDPipeline Expansion or New Partnership Announcement70% success